Stock listing
Cogent Biosciences, Inc.
Selected listing: COGT · BX · CHF · CH
Cogent Biosciences, Inc. (BX Swiss: COGT), Health Technology. Latest release Sep 15, 2026: Cogent Biosciences Announces FDA Acceptance of New Drug Application…
- Ticker
- BX Swiss: COGT
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BX Swiss
- Currency
- CHF
About Cogent Biosciences, Inc.
The company focuses on developing innovative therapies for genetic diseases. Cogent Biosciences aims to address unmet medical needs through its advanced research and development efforts.
Latest news from Cogent Biosciences, Inc.
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
September 15, 2026
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
August 10, 2026
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
June 30, 2026
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
June 12, 2026
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
June 12, 2026
Research Cogent Biosciences, Inc.
Cogent Biosciences, Inc. company profile
View the public company page for Cogent Biosciences, Inc. on 6ix.
Cogent Biosciences, Inc. news
Read company news and market updates connected to Cogent Biosciences, Inc..
Cogent Biosciences, Inc. investor events
Find investor webinars, events, and replay context for Cogent Biosciences, Inc..